Dermatofibrosarcoma protuberans (DFSP) of the face. Photo by Tontonflingueur via Wikimedia Commons Dermatofibrosarcoma protuberans (DFSP) rarely affects the head and face—but when it does, new research suggests the cheek is the prime location. In what is described as the largest clinical cohort of facial DFSP to date, investigators at a single Chinese institution have mapped the complex distribution of the tumour across facial subunits, uncovering distinct anatomic and biolog

Tanning bed use is tied to almost a threefold increase in melanoma risk, and findings from new research show these devices cause melanoma-linked DNA damage across nearly the entire skin surface. The findings were reported in a study published in Science Advances led by Northwestern Medicine in Chicago and the University of California, San Francisco. This new study “irrefutably” challenges claims from the tanning industry that tanning beds are no more harmful than sunlight by

A new analysis in JAMA Dermatology reports that nicotinamide, a form of vitamin B3, was associated with a meaningful reduction in incident skin cancers among U.S. veterans with a prior history of the disease. The findings point to an inexpensive, orally administered chemopreventive option that could help clinicians manage an especially high‑risk population. The study drew on data from more than 12,000 veterans followed over 25 years who had previously received nicotinamide a

Photo by curretett on Freeimages.com Young adults who use tanning beds may be aging their skin cells at a molecular level much faster than their chronological age suggests, according to a new study from the University of California, San Francisco (UCSF) and Northwestern University. The research, published December 12 in Science Advances , reports that tanning bed users in their 30s and 40s harbour more mutations in their skin cells than nonusers who were in their 70s or 80s.

A registry study from Lund University in Sweden shows a possible increased risk of basal cell carcinoma with certain blood pressure medications. Because the risk increase is relatively low, 9% or lower, the researchers do not recommend treatment discontinuation. Instead, physicians should inform their patients that extra sun protection may be needed. The study’s lead author, Johan Kappelin, PhD, is a senior consultant at the dermatology clinic in Landskrona, Sweden. “Basal c

Patients with AD have a higher risk of non-melanoma skin cancers.

Durable, ongoing near-complete response to nivolimab + relatlimab in a 64-year-old with locally-advanced BCC after resistance to 26 weeks of nivolimab alone. Photo by: Evan Lipson, M.D. A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in treatment. Results from the phase 2 clinical trial (NCT03521830), presented Oct. 20 at the European Society

Counties in Pennsylvania near cultivated croplands had significantly higher melanoma rates compared to areas not near farmlands.